GlassScriptPhysician profile
Jose Sanchez
NPI 1497786107
$3,094.53
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,080 · 2022: $1,060 · 2023: $656 · 2024: $102 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.54 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $764.56 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $320.31 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $269.17 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $256.07 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $228.30 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $181.44 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $168.42 | 2021-2023 | Farxiga |
| Astellas Pharma US INC | $160.53 | 2021-2024 | Veozah |
| Vifor Pharma, INC. | $128.23 | 2021-2022 | |
| Boston Scientific Corporation | $114.90 | 2025 | Ekosonic |
| Amarin Pharma, INC. | $92.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $69.05 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $67.18 | 2022-2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $51.69 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.61 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.86 | 2021-2022 | |
| Genentech USA, INC. | $31.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.61 | 2021-2023 | Xifaxan |
| Redhill Biopharma INC. | $24.01 | 2022 | |
| Siemens Medical Solutions USA, INC. | $19.18 | 2025 | Somatom X.Cite |
| Sumitomo Pharma America, INC. | $17.84 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $16.53 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.